BFH772 (VEGFR2 inhibitor): Technical Use and Workflow Guidance

What This Product Solves

BFH772 is a potent, small-molecule VEGFR2 kinase inhibitor developed for research applications focused on the VEGFR2 signaling pathway. Its high selectivity (IC50 = 3 nM for VEGFR2) and minimal activity against related kinases make it particularly suitable for studies requiring precise modulation of VEGFR2-mediated angiogenesis, such as tumor angiogenesis models (product_spec). The compound's selectivity profile reduces off-target effects, aiding in the interpretation of experimental outcomes where specific VEGFR2 inhibition is critical. BFH772 is not recommended for protocols that require water-soluble compounds or broad-spectrum kinase inhibition (internal_article), as its efficacy is significantly reduced against kinases FLK-1, FLT-1, FLT-4, B-RAF, RET, and TIE-2.

Protocol Parameters

• in vitro kinase assay | IC50 = 3 nM | Selective VEGFR2 inhibition | Enables high-affinity, pathway-specific inhibition in cell-free systems | product_spec
• solubility (DMSO) | ≥53.4 mg/mL | Required for stock solution preparation | Ensures adequate compound concentration for typical in vitro and in vivo workflows | product_spec
• solubility (ethanol) | ≥15.33 mg/mL | Alternative for DMSO-incompatible assays | Provides flexibility in solvent choice for protocol compatibility | product_spec
• storage temperature | -20°C | Short- and long-term storage of powder | Maintains compound stability and integrity; long-term solution storage not recommended | product_spec
• in vivo administration | oral (dose not specified) | Tumor angiogenesis model studies | Demonstrated efficacy in suppressing angiogenesis and tumor growth in animal models | product_spec
• solution stability | Immediate use recommended | All workflows | Minimizes degradation and ensures reproducibility; avoid long-term storage of solutions | product_spec

Workflow Setup and QC Checklist

• Compound reconstitution: Prepare stock solutions in DMSO (preferred) or ethanol at concentrations up to the solubility limits (≥53.4 mg/mL in DMSO; ≥15.33 mg/mL in ethanol). Vortex and sonicate as needed to ensure complete dissolution (internal_article).
• Aliquoting and storage: Dispense working aliquots to minimize freeze–thaw cycles. Store powder and solutions at -20°C, but only retain solutions short-term as per product guidelines.
• Purity and identity verification: Review the supplied certificate of analysis (purity >96%) and safety data sheet prior to use. Confirm batch numbers and QC data match experimental records.
• Solvent compatibility check: Ensure assay buffers and cell systems tolerate the chosen solvent and concentration, including DMSO or ethanol final concentrations.
• Control design: Include vehicle-only and off-target kinase controls to validate the specificity of observed effects.
• Documentation: Record lot numbers, preparation date, and storage conditions for traceability and reproducibility.

Common Failure Modes and Fixes

• Incomplete dissolution: If BFH772 does not fully dissolve at the recommended concentrations, increase mixing time, use sonication, or verify solvent purity. Avoid water, as the compound is insoluble.
• Reduced biological activity: Check for excessive freeze-thaw cycles or prolonged storage of stock solutions. Always prepare fresh solutions and store powder at -20°C to maintain activity.
• Unexpected off-target effects: Ensure vehicle and off-target controls are included, and confirm that the VEGFR2 inhibitor concentration is within the selective range to avoid non-specific interactions.
• Solvent toxicity in cell assays: Adjust working concentrations of DMSO or ethanol to levels tolerated by cells (typically ≤0.1–0.5%). Conduct solvent-only control experiments to isolate compound effects.

Scope and Limitations

• Scope: BFH772 is optimized for research targeting the VEGFR2 signaling pathway, especially for studying angiogenesis inhibition in tumor models. Its use is appropriate where high kinase selectivity and compatibility with organic solvents are essential (internal_article).
• Limitations: BFH772 is not suitable for workflows that require water-soluble inhibitors or broad-spectrum kinase inhibition. DMSO/ethanol use may restrict applications in sensitive biological systems. Lack of cross-kinase potency limits its use in multiplexed kinase studies. Protocols requiring long-term solution storage should select alternative compounds.
• Evidence boundaries: All quantitative parameters and recommended protocols derive directly from the product dossier and workflow best practices; no peer-reviewed papers are cited for this compound's specific use.

Conclusion

BFH772 offers a robust solution for researchers requiring a highly selective VEGFR2 inhibitor for angiogenesis and tumor model studies. Strict adherence to recommended solubility, storage, and workflow parameters ensures consistent assay performance and data reliability. For detailed product specifications and handling instructions, refer to the official BFH772 (VEGFR2 inhibitor) page.